Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Dr Reddys Laboratories Ltd is up for a third straight session today. The stock is quoting at Rs 1241.5, up 1.14% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.41% on the day, quoting at 23600.05. The Sensex is at 77920.62, down 0.45%. Dr Reddys Laboratories Ltd has slipped around 8.14% in last one month.
Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has slipped around 5.07% in last one month and is currently quoting at 21868.5, up 0.83% on the day. The volume in the stock stood at 13.75 lakh shares today, compared to the daily average of 20.88 lakh shares in last one month.
The benchmark February futures contract for the stock is quoting at Rs 1237.6, up 1.05% on the day. Dr Reddys Laboratories Ltd is up 0.45% in last one year as compared to a 7.61% jump in NIFTY and a 18.78% jump in the Nifty Pharma index.
The PE of the stock is 19.77 based on TTM earnings ending December 24.
Dr Reddys Laboratories Ltd fell for a fifth straight session today. The stock is quoting at Rs 1176.75, down 0.38% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.71% on the day, quoting at 23121.1. The Sensex is at 76421.63, up 0.69%.Dr Reddys Laboratories Ltd has eased around 14.54% in last one month.Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has eased around 9.36% in last one month and is currently quoting at 20796.6, up 1.29% on the day. The volume in the stock stood at 22.62 lakh shares today, compared to the daily average of 20.2 lakh shares in last one month.
The benchmark January futures contract for the stock is quoting at Rs 1182.5, up 0.81% on the day. Dr Reddys Laboratories Ltd jumped 0.73% in last one year as compared to a 7.43% rally in NIFTY and a 20.58% spurt in the Nifty Pharma index.
The PE of the stock is 18.99 based on TTM earnings ending December 24.
Aditya Birla Fashion & Retail (ABFRL), Bandhan Bank, Can fin Homes, Dixon Technologies(India), L&T Finance, Manappuram Finance, Mahanagar Gas and Punjab National Bank.
Earnings Today:
JSW Steel, Hindustan Petroleum Corporation, Bank of India, InterGlobe Aviation, Godrej Consumer Products, DLF, AU Small Finance Bank, Aditya Birla Money, DAM Capital Advisors, DCB Bank, Fedbank Financial Services, Granules India, Jindal Saw, Laurus Labs, Shriram Finance, Solara Active Pharma Sciences, Supriya Lifescience, Torrent Pharmaceuticals, Trident will declare their earnings later today.
Stocks to Watch:
Dr Reddys Laboratories consolidated net profit increased 2.4% to Rs 1413.70 crore on 15.9% jump in net sales to Rs 8358.60 crore in Q3 FY25 over Q3 FY24.
United Spirits’ consolidated net profit declined 4.3% to Rs 380.23 crore on 14.4% increase in net sales (excluding excise duty) to Rs 3433 crore in Q3 FY25 over Q3 FY24.
Mphasis consolidated net profit increased 1.06% to Rs 427.81 crore in Q3 FY25 as compared with Rs 423.33 crore in Q3 FY24. Revenue from operations jumped 23.9% YoY to Rs 3,230 crore during the quarter.
Mankind Pharma’s consolidated net profit declined 16.2% YoY to Rs 380.23 crore in Q3 FY25. Net sales increased 23.9% to Rs 3230 crore in Q3 FY25 as compared with Rs 2606.95 crore in Q3 FY24.
Jyoti Structures received award for a project worth Rs 741.28 crore from Power grid Corporation of IndiaThe project involves the design, detailing, testing, supply of towers, and all line materials, as well as the commissioning of Package 01 of the ± 800 kV HVDC Bipole Line between KPS2 (HVDC) and Nagpur (HVDC) on a total turnkey basis.
Greenlam Industries’ subsidiary, Greenlam has commenced commercial production of chipboard at its manufacturing facility in Naidupeta, Andhra Pradesh, effective from 23 January 2025. The facility has an installed production capacity of 2,92,380 cubic meters per annum and has the potential to generate revenue of up to Rs 750 crore annually at full capacity utilization. The total capital expenditure incurred for the chipboard project is Rs 735 crore as of the commencement of commercial production.
The stock dropped 4.54% to Rs 1,230.80 amid media reports highlighting concerns over the declining revenue contribution from Revlimid, which has also pressured margins. Revlimid, a blockbuster cancer drug and a significant growth driver for Dr. Reddy's in recent years, is nearing its patent expiry in January 2026, raising fears of a potential revenue decline post-expiry.
A foreign brokerage noted that while the launch of the anti-diabetic drug Semaglutide in Canada in early 2026 could offer some relief to Dr. Reddy's, it is unlikely to fully compensate for the revenue loss from Revlimid. While Dr. Reddy's management has identified other growth drivers, the brokerage believes that Semaglutide will primarily fuel growth in the short term, with other long-term factors expected to contribute later.
The company's selling, general & administrative (SG&A) expenses for Q2 FY25 were at Rs 2,410 crore, YoY increase of 19%. Research & development (R&D) expenses in third quarter of FY25 stood at Rs 670 crore, 8% of revenue.
During the quarter, revenues from emerging markets segment stood at Rs 1,440 crore, year on year increase of 12%, growth is attributable to market share expansion as well as new product launches. Revenues from India market during the quarter stood at Rs 1,350 crore, year on year increase of 14%, Growth was led by revenues from the in-licensed vaccine portfolio, new product launches as well as price increases, partially offset by lower volume pick-up in certain brands in Cardiac and Gastrointestinal therapy areas.
Revenues from the North American market stood at Rs 3,380 crore, reflecting a 1% year-on-year increase. This growth was driven by higher volumes, new product launches, and favorable foreign exchange movements. However, these gains were partially offset by price erosion compared to the previous year.
During the quarter, revenue from Europe market was at Rs 1,210 crore, year on year growth of 143%. The growth includes revenues from the recently acquired NRT portfolio. Underlying growth excluding NRT is 22% YoY.
Revenues from Global Generics (GG) during the quarter grew 17% YoY to Rs 7,380 crore, growth was largely driven by revenues from the acquired NRT portfolio, higher volumes and new product launches.
Revenues from Pharmaceutical Services and Active Ingredients (PSAI) rose 19.51% to Rs 840.70 crore in Q2 FY25, mainly driven by momentum in base business volumes, growth in services business and revenues from new products.
Commenting on the results, Co-Chairman & MD, G V Prasad said, 'We delivered double digit growth aided by our newly acquired NRT business, new launches and improved operational efficiencies. We remain committed to addressing patient needs by advancing healthcare through access, affordability and innovation.'
Dr Reddy's Laboratories is engaged in providing medicines. The firm operates in three segments: global generics, pharmaceutical services and active ingredients (PSAI) and proprietary products.
At 13:25 IST, the barometer index, the S&P BSE Sensex, shed 45.42 points or 0.07% to 76,474.96. The Nifty 50 index fell 20.60 points or 0.09% to 23,184.75.
In the broader market, the S&P BSE Mid-Cap index declined 1.06% and the S&P BSE Small-Cap index fell 1.43%.
The market breadth was weak. On the BSE, 1,188 shares rose and 2,629 shares fell. A total of 136 shares were unchanged.
Economy:
The HSBC Flash India Composite Output Index, which measures the month-on-month change in the combined output of India's manufacturing and service sectors, fell from a final reading of 59.2 in December to 57.9 in January. This indicated the weakest rate of expansion in 14 months. However, the headline figure remained well above its long-term average of 54.7.
While the slowdown at the composite level, driven by the service sector, was evident, there was a pickup in growth among goods producers. The HSBC Flash India Manufacturing PMI, a snapshot of factory business conditions based on new orders, output, employment, supplier delivery times, and stocks of purchases, rose from 56.4 in December to 58.0 in January, reflecting the best improvement in the sector's health since July 2024.
Pranjul Bhandari, Chief India Economist at HSBC, said: “India’s manufacturing sector started the year strong, with output and new orders bouncing back from a relatively weak third fiscal quarter. The rise in new export orders was especially noticeable, and the easing of input cost inflation is also good news for manufacturers. The cooling in growth in new domestic business in the services sector, however, highlights a potentially emerging weak spot in the economy. New export business for service providers, on the other hand, looks set to maintain its growing momentum.”
Gainers & Losers:
Eicher Motors (up 2%), Tata Conusmer Products (up 1.80%), Hindustan Unilever (up 1.65%), Power Grid Corporation of India (up 1.56%) and Grasim Industries (up 1.54%) were the major Nifty gainers.
Dr Reddy Laboratories (down 4.91%), Trent (down 2.53%), Apollo Hospital Enterprise (down 1.90%), Mahindra & Mahindra (down 1.78%) and Cipla (down 1.68%) were the major Nifty losers.
Dr Reddy’s Laboratories dropped 4.91%. The company reported 2.4% increase in consolidated net profit to Rs 1,413.70 crore in Q3 FY25 compared with Rs 1,380.90 crore in Q3 FY24. Net sales jumped 15.9% to Rs 8,358.60 crore in Q3 FY25 as compared with Rs 7,214.80 crore in Q3 FY24.
The media reports highlighting concerns over the declining revenue contribution from Revlimid, which has also pressured margins. Revlimid, a blockbuster cancer drug and a significant growth driver for Dr. Reddy's in recent years, is nearing its patent expiry in January 2026, raising fears of a potential revenue decline post-expiry.
Stocks in Spotlight:
Amber Enterprises India added 3.55% after the company reported consolidated net profit of Rs 35.87 crore in Q3 FY25, compared with net loss of Rs 0.48 crore posted in Q3 FY24. Revenue from operations jumped 64.8% year on year (YoY) to Rs 2,133.33 crore in the quarter ended 31 December 2024.
United Spirits fell 1.14%. The spirits maker's standalone net profit jumped 36.31% to Rs 473 crore in Q3 FY25 as against Rs 347 crore posted in Q3 FY24. Revenue from operations (excluding excise duty) stood at Rs 3,432 crore in Q3 FY25, up 14.82% YoY, mainly driven by resilient consumer demand in peak festive season and a fast scale-up in Andhra Pradesh.
Capri Global Capital (CGCL) rallied 12.01% after the NBFC's consolidated net profit surged 88.41% to Rs 128.08 crore on 35.63% increase in total income to Rs 821.83 crore in Q3 FY25 over Q3 FY24.
Mankind Pharma fell 3.77% after the company’s consolidated net profit declined 16.2% to Rs 380.23 crore in Q3 FY25 as against Rs 453.76 crore posted in Q3 FY24. However, revenue from operations increased 23.9% year on year (YoY) to Rs 3,230 crore in the third quarter of FY25.
V2 Retail hit the upper circuit of 5% after the company’s consolidated net profit surged 117.2% to Rs 51.19 crore in Q3 FY25 compared with Rs 23.57 crore in Q3 FY24. Revenue from operations jumped 58.1% to Rs 590.94 crore in Q3 FY25 compared with Rs 373.76 crore in corresponding quarter last year.
Sona BLW Precision Forgings declined 3.11%. The company reported a 13.93% increase in consolidated net profit to Rs 151.19 crore on 11.02% rise in revenue from operations to Rs 867.91 crore in Q3 FY25 over Q3 FY24.
Thyrocare Technologies dropped 1.03%. The healthcare service provider reported 28.56% increase in consolidated net profit to Rs 18.95 crore on 23.14% rise in revenue from operations to Rs 165.92 crore in Q3 FY25 over Q3 FY24.
Global Markets:
European market advanced as US President Donald Trump called for lower interest rates and cheaper oil prices, additionally investors are also likely to be looking ahead to the Fed’s FOMC meeting on Wednesday with no change expected to interest rates.
Asian market traded mixed on Friday as the Bank of Japan raised its key short-term interest rate to around 0.5%, the highest in 17 years, in an effort to further 'normalize' its monetary policy as inflation remains within target levels.
Inflation in Japan stayed on track in December, supporting the case for the BoJ’s expected interest rate hike. Core CPI, excluding volatile fresh food prices, rose 3% year-on-year, as widely expected. Headline CPI hit 3.6% y-o-y—a two-year high—up from 2.9% in November.
On the downside, Japanese manufacturing activity contracted further in January. The au Jibun Bank Manufacturing PMI dropped to 48.8 from December’s 49.6, marking the seventh consecutive month of contraction. Any reading below 50 signals a shrinking sector.
Chinese equities climbed after U.S. President Donald Trump suggested he would prefer not to impose further tariffs on China during a media interview, easing trade war tensions.
In the U.S., the S&P 500 closed at a record 6,118.72 points on Thursday, up 0.5%. The Dow Jones Industrial Average gained 0.9% to 44,565.26, while the NASDAQ Composite edged up 0.2%. Investors responded positively to robust corporate earnings and Trump’s address at Davos, where he urged for immediate global interest rate cuts.
GE Aerospace shares soared 6.6% after posting better-than-expected Q4 sales and profits. Union Pacific Corporation saw a 5.2% jump in stock price, fueled by strong operational metrics and lower fuel costs. On the flip side, Electronic Arts Inc. tumbled 16.7% after slashing its net bookings guidance, citing weak performance in several games, particularly its soccer franchise. American Airlines Group slid 8.7% as it projected a larger-than-expected Q1 loss due to rising costs, despite exceeding Q4 earnings forecasts.
President Trump, speaking remotely at the World Economic Conference in Davos, Switzerland, addressed global economic issues including interest rates, U.S.-China trade, and energy policies. On monetary policy, he urged for immediate interest rate cuts worldwide, emphasizing their importance for economic growth.